Hacker News Reader

Parent Full thread

simonsarris

Eli Lilly has GLP-1 injectables and will have an oral pill this year. Novo Nordisk has already dropped that ball.

Hence Eli Lilly +40% in the last year and Novo -23%. Or on a longer timescale you can see the problem:

https://www.google.com/finance/quote/NVO:NYSE?sa=X&sqi=2&ved...

View on HN

What should they have done differently to prevent a competitor from entering a valuable market?

"Pricing power fell when someone else entered the market" isn't dropping a ball is why I ask.

I think they meant dropped the ball on oral intake.

Most people probably prefer a pill vs injections with needles.

Novo nordisk's biggest mistake was refusing to create a direct to consumer business. Eli Lilly sells most of their product through their website at large discounts, this superior distribution method is largely how they were able to gain such a large market share. Their product is also better than ozempic, so that definitely helped too. But its not like Novo Nordisk was stuck with ozempic, they couldve developed new advancements as well.

Reply on news.ycombinator.com